Eye Cancer Clinical Trial
Official title:
Social-Psychological Aspects of Survivorship in Cancer Patients After Orbital Exenteration: Issues Stemming From Alterations of Normal Facial Appearance
The goal of this research study is to learn about the social and emotional factors that may affect the quality of life of patients with cancer of the eye or eye area who have had their facial appearance changed due to an orbital exenteration.
Family Members:
Study Interview:
If you agree to take part in this study, you will meet with a research staff member
(preferably in person, or else by phone) for an interview. During the interview, you will be
asked questions about your demographic information (such as your age, education level, and
marital status). You will be asked about your family member's medical history, emotional
well-being, appearance, and the types of social relations and support in his/her life (such
as relationships with friends and family).
You will also be asked if and how these social relations may have been affected by his/her
cancer experiences after the orbital exenteration. The interview should take about 2 to 2
1/2 hours. It will be audio-taped, and the interviewer will be taking notes. Your responses
in the interview will not be shared with the patient.
Additional Information:
If your interview responses show that you may be having emotional difficulties or
depression, you will be provided with names of mental health providers in case you would
like to receive mental health screening.
Length of Study Participation:
After the interview, your participation in this study will be over.
This is an investigational study.
Up to 40 people (20 patients and 20 family members) will take part in this study. All will
be enrolled at MD Anderson.
Patients:
Study Interview:
If you agree to take part in this study, a research staff member will schedule you for an
interview. During the interview, you will be asked questions about your demographic
information (such as your age, education level, and marital status) and medical history. You
will also be asked about your emotional well-being, how you feel about your appearance, how
you are coping with the cancer, and the types of social relations and support you have in
your life (such as relationships with friends and family). The interview should take about 2
to 2 1/2 hours. It will be audio-taped, and the interviewer will be taking notes.
Additional Information:
Your responses in the interview will not be shared with your doctor. If you feel you need a
doctor's opinion about anything that is asked about in the questionnaire (such as mental or
emotional difficulties), please contact your doctor.
If your interview responses show that you may be having emotional difficulties or
depression, you will be provided with names of mental health providers in case you would
like to receive mental health screening.
Interview for Family Members:
For each eligible patient who agrees to take part in this study, one family member must also
agree to participate. Researchers will ask you for a family member whom researchers can
contact by phone to ask if he or she would agree to take part in this study. Your family
member's participation would involve being interviewed about his or her opinions of the same
questions that you were asked about in your interview. If your family member agrees, his or
her interview will be scheduled. If that family member does not agree to take part, another
family member may take part in his or her place. If no family members agree to take part,
your interview will not be scheduled and you will not be enrolled on the study.
Length of Study Participation:
After you complete the interview, your participation in this study will be over.
This is an investigational study.
Up to 40 people (20 patients and 20 family members) will take part in this study. All will
be enrolled at MD Anderson.
;
Observational Model: Family-Based, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01151748 -
Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma
|
Phase 2 | |
Completed |
NCT00588640 -
Study of D-Methadone in Patients With Chronic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT05853315 -
BCC Excision Revisited
|
||
Active, not recruiting |
NCT01653080 -
MRI in Diagnosing Solid Tumors of the Eye and Orbit
|
N/A | |
Completed |
NCT00020267 -
Vaccine Therapy in Treating Patients With Metastatic Cancer
|
Phase 1 | |
Completed |
NCT05236049 -
Use of an Allograft Set-up (SclerFIX) as Replacement of Sclera Graft for Support of Enucleation Implant
|
Phase 1 | |
Completed |
NCT01072253 -
Quality of Life of Eye Amputated Patients in Denmark
|
N/A |